InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.368 0.008 (2%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$112 Phase II ABSSSI Clinical Trial Advances to Final Stages 5 Nov 2024 10:12AM $0.445 $0.368 fallen by 17.42%
$112 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2024 6:20PM $0.470 $0.368 fallen by 21.81%
$112 Efficacy Data & Approval to Continue Ph II ABSSSI Trial 28 Oct 2024 9:44AM $0.505 $0.368 fallen by 27.23%
$112 Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway 9 Oct 2024 9:07AM $0.535 $0.368 fallen by 31.31%
$112 Notice of Special General Meeting/Proxy Form 8 Oct 2024 12:59PM $0.540 $0.368 fallen by 31.94%
$112 Notice of Annual General Meeting/Proxy Form 8 Oct 2024 12:57PM $0.540 $0.368 fallen by 31.94%
$112 Notification of buy-back - RCE 8 Oct 2024 12:52PM $0.540 $0.368 fallen by 31.94%
$112 Cleansing Notice 26 Sep 2024 12:12PM $0.515 $0.368 fallen by 28.64%
$112 Application for quotation of securities - RCE 26 Sep 2024 12:04PM $0.510 $0.368 fallen by 27.94%
$112 2024 Annual General Meeting 16 Sep 2024 4:47PM $0.515 $0.368 fallen by 28.64%
$112 Appendix 4G 30 Aug 2024 5:19PM $0.495 $0.368 fallen by 25.76%
$112 Annual Report to Shareholders 30 Aug 2024 5:18PM $0.495 $0.368 fallen by 25.76%
$112 Preliminary Final Report 30 Aug 2024 5:14PM $0.495 $0.368 fallen by 25.76%
$112 Securities Trading Policy 6 Aug 2024 5:26PM $0.480 $0.368 fallen by 23.44%
$112 Application for quotation of securities - RCE 6 Aug 2024 11:49AM $0.490 $0.368 fallen by 25%
$112 Successful Completion of Share Purchase Plan 5 Aug 2024 9:28AM $0.465 $0.368 fallen by 20.97%
$112 Quarterly Activities/Appendix 4C Cash Flow Report 26 Jul 2024 10:44AM $0.460 $0.368 fallen by 20.11%
$112 US Department of Defense Grants US $2m for R327G 15 Jul 2024 9:50AM $0.460 $0.368 fallen by 20.11%
$112 Change of Auditor 11 Jul 2024 3:25PM $0.465 $0.368 fallen by 20.97%
$112 Share Purchase Plan - Letter and Offer Booklet 10 Jul 2024 9:37AM $0.465 $0.368 fallen by 20.97%
$112 Cleansing Notice 9 Jul 2024 10:05AM $0.460 $0.368 fallen by 20.11%
$112 Application for quotation of securities - RCE 9 Jul 2024 9:59AM $0.460 $0.368 fallen by 20.11%
$112 R327 Efficacy against WHO Priority Pathogen Acinetobacter B 8 Jul 2024 9:53AM n/a $0.368 n/a
$112 Equity Raising Presentation 2 Jul 2024 10:25AM $0.600 $0.368 fallen by 38.75%
$112 Proposed issue of securities - RCE 2 Jul 2024 10:23AM $0.600 $0.368 fallen by 38.75%

126 - 150 of 725 results

Page 6 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.